

Main Scientific Publications – Prof. Choi

1. Comparison of the data of a next-generation sequencing panel from K-MASTER project with that of orthogonal methods for detecting targetable genetic alterations. Choi YJ, Choi JY, Kim JW, Lim AR, Lee Y, Chang WJ, Lee S, Sung JS, Chung H-J, Lee JW, Kang EJ, Kim JS, Lim T, Kim HS, Kim YJ, Ahn MS, Kim YS, Park JH, Lim S, Cho SS, Cho JH, Sin SW, Park KH, Kim YH. *Cancer Res Treat.* 2021 May. Online Ahead of print.
2. E-cigarette and cigarette use among cancer survivors versus general population: a case-control study in Korea. Paek J, Son S, Choi YJ. *J Cancer Surviv.* 2021 Jun 16. Online Ahead of print.
3. 2020 Korean guidelines for the management of metastatic prostate cancer. Kim I-H, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim H-J, Maeng CH, Park K, Park I, Bae WK, Sohn BS, Lee M-Y, Lee JL, Lee J, Lim ST, Lim JH, Chang H, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. *Korean J Intern Med.* 2021 Feb 10.
4. Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Byeon S, Kang MJ, Choi YJ, Kim YJ, Kim M, Yun J, Yi SY, Kim JY, Kim ST, Lee J. *Transl Cancer Res* 2020;9(5):3222-3230. (co-first)
5. Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer. Kang EJ, Choi YJ, Lee SR, Sung HJ, Kim JS. *Korean J Intern Med.* 2020 Nov;35(6):1468-1476 (co-first)
6. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent osteoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Kang J, Choi YJ, Seo BY, Jo U, Park SI, Kim YH, Park KH. *Sci Rep.* 2019 Jun 19;9(1):8726.
7. Association between hand grip strength and impaired health-related quality of life in Korean cancer survivors: a cross-sectional study. Paek J, Choi YJ. *BMJ Open.* 2019 Sep 8;9(9):e030938.
8. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). Choi YJ, Kim HS, Park SH, Kim B-S, Kim KH, Lee HJ, Song HS, Shin D-Y, Lee HY, Kim H-G, Lee KH, Lee JL, Park KH. *Cancer Res Treat.* 2018 Oct;50(4):1252-1259.
9. A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin. Kim JS, Lim SY, Hwang J, Kang EJ, Choi YJ. *J Korean Med Sci.* 2017;32:1879-1884.
10. The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer. Choi YJ, Chang WJ, Shin SW, Park KH, Kim ST, Kim YJ. *Oncotargets and Therapy.* 2016;9:3307-3312.
11. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. Choi YJ, Lee DH, Choi CM, Lee JS, Lee SJ, Ahn J-H, Kim S-W. *BMC Cancer.* 2015;15:763.
12. Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study. Choi YJ, Lee SH, Ahn J-H, Lee K-H, You D, Hong B, Hong JH, Ahn H. *Br J Cancer.* 2015;112:260-265.
13. Pretreatment serum level of 15-kDa granulin might have a prognostic value in patients with diffuse large B cell lymphoma. Park Y, Choi YJ, Park SJ, Lee SR, Sung HJ, Park KH, Kim SJ, Choi CW, Jung KY, Kim BS. *Acta Haematol.* 2011;126(2):79-86.

14. Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. *Chemotherapy*. 2011;57(2):108-14
15. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. *Clin Oncol (R Coll Radiol)*. 2012 Mar;24(2):105-11.
16. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. Kang EJ, Choi YJ, Kim JS, Kim ST, Park KH, Choi IK, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. *Asia Pac J Clin Oncol*. 2010 Dec;6(4):286-91.
17. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu and M-H Ryu. *Br J Cancer*. 2013 Oct 29; 109(9):2309-15.
18. Predictors of mortality attributable to *Clostridium difficile* infection in patients with underlying malignancy. Yoon YK, Kim MJ, Sohn JW, Kim HS, Choi YJ, Kim JS, Kim ST, Park KH, Kim SJ, Kim BS, Shin SW, Kim YH, Park Y. *Supportive Care Cancer*. 2014;22:2039-2048.
19. Prognostic factors for the selection of patients eligible for second-line chemotherapy in advanced biliary tract cancer. Kang EJ, Choi YJ, Kim JS, Park KH, Oh SC, Seo JH, Kim HJ, Kang KW, Yu ES, Shin SW, Kim YH, Kim JS. *Chemotherapy*. 2014;60:91-98.
20. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. Lee J-L, Park SH, Koh S-J, Kim YJ, Choi YJ, Lee J, Lim HY. *Cancer Chemother Pharmacol*. 2014;74:1005-1013.
21. Bladder and liver involvement of visceral leishmaniasis may mimic malignancy. Kang EJ, Choi YJ, Kim JS, Lee BH, Kang K-W, Kim HJ, Yu ES, Kim YH. *Cancer Res Treat*. 2014;46(4):419-424.
22. Novel germline mutation of BRCA1 gene in a 56-year-old woman with breast cancer, ovarian cancer, and diffuse large B-cell lymphoma. Kim HS, Lee SW, Choi YJ, Shin SW, Kim YH, Cho MS, Lee SN, Park KH. *Cancer Res Treat*. 2015 Jul;47(3):534-8.
23. A Prognostic index to identify patients with intrahepatic cholangiocarcinoma who could benefit from gemcitabine plus cisplatin. Lee S-Y, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Kim ST. *Am J Ther*. 2015 Jan 29. (Epub)
24. Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer? Kim ST, Shang WJ, Kim L, Sung JS, Choi YJ, Kim YH. *Cancer Res Treat*. 2015;47(4):796-803.
25. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. Kim HA, Ahn SH, Nam SJ, Park S, Ro J, Im SA, Jung YS, Yoon JH, Hur MH, Choi YJ, Lee SJ, Jeong J, Cho SH, Kim SY, Lee MH, Kim LS, Moon BI, Kim TH, Park C, Kim SJ, Jung SH, Park H, Gwak GH, Kang SH, Kim JG, Kim J, Choi SY, Lim CW, Kim D, Yoo Y, Song YJ, Kang YJ, Jung SS, Shin HJ, Lee KJ, Han SH, Lee ES, Han W, Kim HJ, Noh WC. *BMC Cancer*. 2016;16:319.
26. Prognostic value of axillary nodal ratio after neoadjuvant chemotherapy of doxorubicin/cyclophosphamide followed by docetaxel: a multicenter retrospective cohort study. Kim SH, Jung KH, Kim T-Y, Im S-A, Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ, Lee S, Sohn JH, Park Y-H, Im Y-H, Ahn J-H, Kim S-B, Kim JH. *Cancer Research and Treatment*. 2016;48(4):1373-1381.
27. Incidence and predictors of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy in Korea. Kim HS, Lee SY, Kim JW, Choi YJ, Park IH, Lee KS, Seo JH, Shin SW, Kim YH, Kim JS, Park KH. *Oncology*. 2016;91(5):274-282.
28. Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive fibromatosis. Park KH, Choi YJ, Kim KW, Ro KH, Kang CH, Song SH, Park JH.

- Jpn J Clin Oncol.2016;46(9):845-9.
29. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, Kim JS, Kang EJ. *OncoTargets Ther.* 2017;10:2983-2992.
 30. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Park YH, Kim TY, Im YH, Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH, Choi YJ, Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH. *Cancer Res Treat.* 2017;49(2):423-429.
 31. Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Kim HJ, Lee SY, Kim DS, Kang EJ, Kim JS, Choi YJ, Oh SC, Seo JH, Kim JS. *Korean J Intern Med.* 2018 Oct 26.
 32. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. Choi JY, Cho EY, Choi YJ, Lee JH, Jung SP, Cho KR, Kim CY, Kim YH, Park KH. *Breast Cancer Res Treat.* 2018 Aug;171(1):181-188.
 33. Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion amplicon cancer hotspot panel and droplet digital polymerase chain reaction. Sung JS, Chong HY, Kwon NJ, Kim HM, Lee JW, Kim B, Lee SB, Park CW, Choi JY, Chang WJ, Choi YJ, Lee SY, Kang EJ, Park KH, Kim YH. *Oncotarget.* 2017 Nov 15;8(63):106901-106912.
 34. Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer. Hyun MH, Sung JS, Kang EJ, Choi YJ, Park KH, Shin SW, Lee SY, Kim YH. *Oncotarget.* 2017 Oct 10;8(55):94417-94430.
 35. Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study. Kim JS, Kang EJ, Kim DS, Choi YJ, Lee SY, Kim HJ, Seo HY, Kim JS. *BMC Cancer.* 2018 Dec 17;18(1):1260.
 36. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent osteoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Kang J, Choi YJ, Seo BY, Jo U, Park SI, Kim YH, Park KH. *Sci Rep.* 2019 Jun 19;9(1):8726.
 37. Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer. Hyun MH, Lee ES, Eo JS, Kim S, Kang EJ, Sung JS, Choi YJ, Park KH, Shin SW, Lee SY, Kim YH. *Lung Cancr.* 2019 Aug;134:158-166.
 38. Completion rate of physician orders for life-sustaining treatment for patients with metastatic or recurrent cancer: a preliminary, cross-sectional study. Kim JW, Choi JY, Jang WJ, Choi YJ, Choi YS, Shin SW, Kim YH, Park KH. *BMC Palliat Care.* 2019 Oct 22;18(1):84.
 39. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomized phase II study (COACH, KCSGGU10-16). Park I, Kim BS, Lim HY, Kim HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL. *Eur J Cancer.* 2019 Oct 24. pii: S0959-8049(19)30727-0.
 40. Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer. Lee SY, Choi YJ, Seo JH, Lee SY, Kim JS, Kang EJ. *J Thorac Dis.* 2019 Nov;11(11):4562-4572.
 41. Innovative countermeasures can maintain cancer care continuity during the coronavirus disease-2019 pandemic in Korea. Lee S, Lim A-R, Kim MJ, Choi YJ, Kim JW, Park KH, Shin SW, Kim YH. *Eur J Cancer.* 2020 Sep;136:69-75.
 42. Pembrolizumab-Induced Myasthenic Crisis with HyperCKemia in a Patient with Thymoma. Shin JH, Choi YJ, Lee J, Baek SH. *J Clin Neurol.* 2020 Jul;16(3):497-498.
 43. Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer. Choi JY, Choi S, Lee M, Park YS, Sung JS, Chang WJ, Kim JW, Choi YJ, Kim J, Kim D-S, Lee S-H, Seok J, Park KH, Kim SH, Kim YH. *Cancer Res Treat.* 2020 Jul;52(3):764-778.
 44. The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA. Chang WJ, Sung JS, Lee SY, Kang EJ, Kwon N-J, Kim HM,

- Shin SW, Choi JY, ChoiYJ, Kim JW, Park KH, Kim YH. Clin Med. 2020 Aug 14;9(8):2642.
45. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Lee Y, Lee S, Sung JS, Chung H-J, Lim A-R, Kim JW, Choi YJ, Park KH, Kim YH. Cancer Res Treat. 2021 Jan;53(1):123-130. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. Bang S-M, Kang J-H, Hong MH, Ahn J-S, Oh SY, Baek JH, Choi YJ, Shin SH, Kim Y-J, Gil H-Y, Park H-E, Lee J, Park E-L. Clin Appl Thromb Hemost. Jan-Dec 2021;27:1076029620979575.